Oxford Immunotec closes £7M series B financing

Oxford Immunotec, the T cell diagnostics company, has announced that it has closed a ТЃ7M series B private equity financing. The round was led by Prelude Ventures, who invested ТЃ2.75M, alongside Quester, the Dow Chemical Company, and Top Technology. Oxford Immunotec will use the financing to extend marketing for its first product, T SPOTт„Ђ-TB, a diagnostic test for tuberculosis (TB), currently approved for sale in Europe.